Would you consider adjuvant endocrine therapy for DCIS in a patient who received bilateral nipple-sparing mastectomies?
Endocrine therapy is usually not indicated for DCIS s/p bilateral mastectomy, but would the fact that residual tissue (nipple-sparing) alter your decision?
Answer from: Medical Oncologist at Academic Institution
No. This is chemoprophylaxis, and the very small amount of remnant breast tissue does not denote a risk of subsequent breast disease high enough to justify the toxicities and risks of endocrine therapy.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree in general. There are some circumstances where I would consider using tamoxifen; for example, someone with a higher-than-average risk of recurrence (i.e. those with BRCA gene mutations, very extensive DCIS, close margins, more than minimal residual breast tissue--which may be hard to determi...
Comments
Medical Oncologist at Albert Einstein College of Medicine/Montefiore Health System
Would you give it in someone young with multifocal...
Would you give it in someone young with multifocal...
Medical Oncologist at Onc San Antonio
It would be mT1mic; was there a SNL done? Might b...
It would be mT1mic; was there a SNL done? Might b...